BRPI0012688B8 - método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas - Google Patents

método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas

Info

Publication number
BRPI0012688B8
BRPI0012688B8 BRPI0012688A BRPI0012688A BRPI0012688B8 BR PI0012688 B8 BRPI0012688 B8 BR PI0012688B8 BR PI0012688 A BRPI0012688 A BR PI0012688A BR PI0012688 A BRPI0012688 A BR PI0012688A BR PI0012688 B8 BRPI0012688 B8 BR PI0012688B8
Authority
BR
Brazil
Prior art keywords
compound
peptide
microbial cells
host microbial
vector
Prior art date
Application number
BRPI0012688A
Other languages
English (en)
Portuguese (pt)
Inventor
Hosoda Hiroshi
Matsuo Hisayuki
Kangawa Kenji
Kojima Masayasu
Minamitake Yoshiharu
Original Assignee
Kangawa Kenji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangawa Kenji filed Critical Kangawa Kenji
Publication of BRPI0012688B1 publication Critical patent/BRPI0012688B1/pt
Publication of BRPI0012688B8 publication Critical patent/BRPI0012688B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0012688A 1999-07-23 2000-07-24 método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas BRPI0012688B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP210002/1999 1999-07-23
JP21000299 1999-07-23
JP33884199 1999-11-29
JP338841/1999 1999-11-29
JP126623/2000 2000-04-26
JP2000126623 2000-04-26
PCT/JP2000/004907 WO2001007475A1 (en) 1999-07-23 2000-07-24 Novel peptides

Publications (2)

Publication Number Publication Date
BRPI0012688B1 BRPI0012688B1 (pt) 2018-06-05
BRPI0012688B8 true BRPI0012688B8 (pt) 2021-05-25

Family

ID=27329078

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0012688A BRPI0012688B8 (pt) 1999-07-23 2000-07-24 método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas
BR0012688-8A BR0012688A (pt) 1999-07-23 2000-07-24 Novos peptìdios

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0012688-8A BR0012688A (pt) 1999-07-23 2000-07-24 Novos peptìdios

Country Status (16)

Country Link
US (5) US7385026B1 (enExample)
EP (3) EP1197496B8 (enExample)
JP (2) JP3471780B2 (enExample)
KR (1) KR100827973B1 (enExample)
CN (2) CN100506844C (enExample)
AT (2) ATE366813T1 (enExample)
AU (2) AU784035B2 (enExample)
BR (2) BRPI0012688B8 (enExample)
CA (2) CA2380058C (enExample)
CY (2) CY1107724T1 (enExample)
DE (2) DE60043361D1 (enExample)
DK (2) DK1795598T3 (enExample)
ES (3) ES2288151T3 (enExample)
IL (2) IL147652A0 (enExample)
PT (2) PT1197496E (enExample)
WO (1) WO2001007475A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7385026B1 (en) 1999-07-23 2008-06-10 Kenji Kangawa Modified ghrelin polypeptides
CA2392019A1 (en) * 1999-11-22 2001-05-31 Zymogenetics, Inc. Method of forming a peptide-receptor complex with zsig33
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
US7141646B2 (en) 2000-05-12 2006-11-28 Kaneka Corporation Method of purifying vinyl polymer
JP2004514651A (ja) 2000-05-30 2004-05-20 メルク　エンド　カムパニー　インコーポレーテッド グレリン類似体
US20020187938A1 (en) * 2000-07-24 2002-12-12 Romano Deghenghi Ghrelin antagonists
EP1493747B1 (en) * 2002-04-11 2012-12-19 Daiichi Sankyo Company, Limited Process for producing modified peptide
CA2471879C (en) * 2002-05-21 2014-02-25 Daiichi Suntory Pharma Co., Ltd. Pharmaceutical composition containing ghrelin
US20040076645A1 (en) * 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates
AU2003254119B2 (en) 2002-07-23 2007-11-29 Ipsen Pharma S.A.S. Ghrelin analogs
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
MXPA05002991A (es) * 2002-09-18 2005-10-05 Univ Montreal Ct Hospitalier Chum Analogos de ghrh.
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
JP4467518B2 (ja) * 2003-04-30 2010-05-26 賢治 寒川 肝障害予防治療剤
EP1633397A2 (en) * 2003-06-04 2006-03-15 Eli Lilly And Company Anti-ghrelin fab antibodies
US20060233788A1 (en) * 2003-09-05 2006-10-19 Heiman Mark L Anti-ghrelin antibodies
CN1321131C (zh) * 2003-12-26 2007-06-13 李宁 猪Ghrelin衍生物及其编码基因与应用
CA2553594A1 (en) * 2004-01-20 2005-07-28 Cytos Biotechnology Ag Particle-induced ghrelin immune response
US7026175B2 (en) 2004-03-29 2006-04-11 Applied Materials, Inc. High throughput measurement of via defects in interconnects
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
US20080171700A1 (en) * 2004-04-07 2008-07-17 Gastrotech Pharma A/S Use Of Secretagogue For The Teatment Of Ghrelin Deficiency
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
CA2566703A1 (en) * 2004-05-11 2005-11-24 Vishwa Deep Dixit Methods of inhibiting proinflammatory cytokine expression using ghrelin
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
CA2569235A1 (en) * 2004-07-14 2006-02-23 Eli Lilly And Company Anti-ghrelin antibodies
EP1812044A2 (en) * 2004-10-27 2007-08-01 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
US20080300180A1 (en) * 2004-11-30 2008-12-04 Gastrotech Pharma A/S Growth Hormone Secretagogue Receptor 1A Ligands
JP4843827B2 (ja) * 2005-02-23 2011-12-21 国立大学法人京都大学 膵臓β細胞の再生促進剤及び膵臓β細胞におけるインスリン産生促進剤
EP1856154A1 (en) * 2005-02-23 2007-11-21 Eli Lilly And Company Humanized anti-ghrelin antibodies
RU2427587C2 (ru) * 2005-09-28 2011-08-27 Ипсен Фарма С.А.С. Аналоги грелина
ES2740108T3 (es) 2005-09-29 2020-02-05 Ipsen Pharma Composición para uso en el tratamiento de dismotilidad gastrointestinal
US20090305969A1 (en) * 2005-11-21 2009-12-10 Noboru Murakami Skin Repair Accelerating Therapeutic Agent Containing Desacyl Ghrelin and Derivatives Thereof as Active Ingredient
US20090181888A1 (en) * 2005-11-21 2009-07-16 Noboru Murakami Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient
WO2007106385A2 (en) 2006-03-10 2007-09-20 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
CN101443358B (zh) 2006-03-13 2016-05-11 利亚特·明茨 生长素释放肽剪接变体在治疗恶病质和/或压食和/或厌食-恶病质和/或营养不良和/或脂肪营养障碍和/或肌肉消耗和/或刺激食欲中的用途
CN101500602A (zh) * 2006-08-01 2009-08-05 斯克里普斯研究院 控制肥胖症的疫苗及方法
JPWO2008018600A1 (ja) 2006-08-11 2010-01-07 国立大学法人 宮崎大学 グレリン及びその誘導体又はＧＨＳ−Ｒ１ａに作用する物質を有効成分とする脊髄神経修復促進治療剤
WO2008018597A1 (fr) * 2006-08-11 2008-02-14 University Of Miyazaki Agent thérapeutique permettant d'accélérer la réparation des nerfs rachidiens comprenant en tant que matière active de la désacyl ghréline ou un dérivé de celle-ci
MX2009003246A (es) 2006-09-27 2009-07-29 Ipsen Pharma Sas Análogos de ghrelina sustituidos en el terminal n.
HRP20160303T1 (hr) 2008-05-23 2016-04-22 Daiichi Sankyo Company, Limited Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi
NZ606427A (en) 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
WO2010132580A2 (en) * 2009-05-12 2010-11-18 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9078868B2 (en) 2010-01-15 2015-07-14 University Of Miyazaki Therapeutic agent for accelerating recovery of animal under medical treatment
CA2805406A1 (en) 2010-06-16 2011-12-22 Mcgill University Growth hormone secretatogue receptor antagonists and uses thereof
WO2012117592A1 (ja) 2011-03-03 2012-09-07 国立大学法人宮崎大学 高体温治療剤
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
EP2819788B1 (en) 2012-02-27 2018-08-22 Amunix Operating Inc. Xten conjugate compositions and methods of making same
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
AU2013335678B9 (en) * 2012-10-24 2024-12-12 Daiichi Sankyo Company,Limited Therapeutic agent for amyotrophic lateral sclerosis
JP6143270B2 (ja) * 2013-01-31 2017-06-07 学校法人東京薬科大学 マイオスタチン阻害ペプチド
EP2979702A4 (en) * 2013-03-25 2016-11-16 Zeria Pharm Co Ltd GASTROKINETIC POSTPRANDIAL MEDIUM
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
CN109879935B (zh) * 2019-03-04 2020-11-20 南京工业大学 一种多肽的液相合成方法
BR112022009217A2 (pt) 2019-11-13 2022-08-02 Amunix Pharmaceuticals Inc Polipeptídeos xten com código de barras e composições destes, e métodos para produzir e usar os mesmos
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
CN120818010B (zh) * 2025-09-18 2025-12-05 天津科技大学 一种来自植物乳杆菌属细胞外囊泡的短肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
DE69332471T2 (de) * 1992-04-07 2003-08-28 The Scripps Research Institute, La Jolla Verfahren zur herstellung modifizierten proteine
CA2216755A1 (en) * 1995-03-31 1996-10-03 Brian Lee Buckwalter Peptides with growth promotion properties
IL118473A0 (en) 1995-06-02 1996-09-12 Suntory Ltd Staphylococcus aureus V8 protease genes coding therefor and a method for the production thereof
JP3982866B2 (ja) 1996-03-04 2007-09-26 アスビオファーマ株式会社 分泌型Ｋｅｘ２誘導体の製造方法
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
JP4335318B2 (ja) 1997-03-24 2009-09-30 ザイモジェネティクス，インコーポレイティド モチリン相同体
IL139686A0 (en) * 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1120846C (zh) * 1999-02-13 2003-09-10 中国人民解放军军事医学科学院基础医学研究所 生长激素释放肽及其应用
US6420521B1 (en) * 1999-06-30 2002-07-16 Zymogenetics, Inc. Short gastrointestinal peptides
US7385026B1 (en) * 1999-07-23 2008-06-10 Kenji Kangawa Modified ghrelin polypeptides

Also Published As

Publication number Publication date
US8524871B2 (en) 2013-09-03
JP4227857B2 (ja) 2009-02-18
EP1197496B8 (en) 2007-10-03
CN1362968A (zh) 2002-08-07
ATE366813T1 (de) 2007-08-15
DK1795598T3 (da) 2010-02-01
CA2380058A1 (en) 2001-02-01
ES2288151T3 (es) 2008-01-01
EP1795598A1 (en) 2007-06-13
AU6023100A (en) 2001-02-13
CY1107724T1 (el) 2013-04-18
CN101693736A (zh) 2010-04-14
KR20020026543A (ko) 2002-04-10
EP1197496A4 (en) 2002-11-20
ES2335235T3 (es) 2010-03-23
DE60043361D1 (de) 2009-12-31
US9573986B2 (en) 2017-02-21
JP2004000251A (ja) 2004-01-08
ES2401939T3 (es) 2013-04-25
CA2696819C (en) 2015-07-07
EP1795598B1 (en) 2009-11-18
AU2006201580B2 (en) 2009-01-08
US20110184153A1 (en) 2011-07-28
CY1109714T1 (el) 2014-08-13
IL147652A0 (en) 2002-08-14
PT1197496E (pt) 2007-08-29
DE60035502T2 (de) 2008-03-20
CN100506844C (zh) 2009-07-01
EP1197496A1 (en) 2002-04-17
US20090170763A1 (en) 2009-07-02
WO2001007475A1 (en) 2001-02-01
JP3471780B2 (ja) 2003-12-02
US8227570B2 (en) 2012-07-24
US20100240866A1 (en) 2010-09-23
US7385026B1 (en) 2008-06-10
AU2006201580A1 (en) 2006-05-18
KR100827973B1 (ko) 2008-05-21
AU784035B2 (en) 2006-01-19
CA2380058C (en) 2011-08-09
PT1795598E (pt) 2010-01-05
IL147652A (en) 2010-04-29
ATE449174T1 (de) 2009-12-15
EP1197496B1 (en) 2007-07-11
EP2119785A1 (en) 2009-11-18
CA2696819A1 (en) 2001-02-01
US9938332B2 (en) 2018-04-10
US20130172251A1 (en) 2013-07-04
BRPI0012688B1 (pt) 2018-06-05
DE60035502D1 (de) 2007-08-23
BR0012688A (pt) 2002-04-16
CN101693736B (zh) 2020-09-11
DK1197496T3 (da) 2007-10-22
EP2119785B1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
BRPI0012688B8 (pt) método para produzir um composto tipo peptídeo, vetor compreendendo um dna que codifica o composto tipo peptídeo, células microbianas hospedeiras e células microbianas hospedeiras transformadas
WO2003077648A3 (en) Methods for the identification of herbicides and the modulation of plant growth
BR0115748B1 (pt) "sistema para o tratamento de água de lastro em uma embarcação, método para o controle de organismos em água de lastro de uma embarcação, e, sistema para a geração de biocida modular em uma embarcação".
NO20005161L (no) N,N-disubstituerte amider som inhiberer bindingen av integriner til deres reseptorer
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
BR0213139A (pt) Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
WO2009051439A3 (en) Method of identifying agents which modulate the activity of calcium-activated chloride channel
WO2002061076A1 (fr) Proteine associee a l'adiponectine
DE69925371D1 (de) Impfstoff für geflügel
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
BR0315247A (pt) Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
EP1609861A4 (en) ION CHANNEL ACTIVITY INHIBITABLE LOW-MOLECULAR PEPTIDES
DE69734764D1 (de) Eine amidgruppe tragende schwefelhaltige verbindungen, verfahren zu ihrer herstellung, deren verwendung in medikamenten und sie enthaltende pharmazeutische zubereitungen
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
DK1074264T3 (da) Inhibitorer for neovaskularisering
BR0303475A (pt) Sal cristalino do ácido adìpico da amlodipina, respectivo método de preparação e composição farmacêutica
DK514582A (da) Cycloalkyl-(alfa-triazolyl-beta-hydroxy)-ketoner, fremgangsmaade til deres fremstilling samt deres anvendelse som fungicider og plantevaekstregulatorer
DE60225699D1 (de) Nierenspezifischer urattransporter und dessen gen
PT1280812E (pt) Ciclipostinas, processo para a sua preparacao e sua utilizacao
DE60313444D1 (de) Vegf-peptide und deren verwendung
AU2003202489A1 (en) Screening method
WO2003022300A1 (en) Preventives/remedies for bone/joint diseases
EP1282641A4 (en) Cervical cancer suppressing protein in women, polynucleotide encoding it, cell transformed by polynucleotide, and method of suppressing proliferation of cancer cells using the expression vector
ES2299823T3 (es) Composicion farmaceutica para acidificacion intracelular con acido cis-urocanico.
WO2000052147A3 (en) Bacterial prolyl peptidases and methods of use